Brexpiprazole

US label (REXULTI, Otsuka, label date 2026-05-06). The label carries three adult indications with different targets — confirm which indication this page covers. Adjunctive treatment of MDD in adults: start 0.5 mg or 1 mg once daily, titrate to 1 mg once daily then to the target of 2 mg once daily, increasing at weekly intervals based on response and tolerability; maximum 3 mg/day. Agitation associated with dementia due to Alzheimer's disease: 0.5 mg once daily Days 1-7, 1 mg once daily Days 8-14, 2 mg once daily from Day 15 (target 2 mg once daily), may increase to a maximum of 3 mg once daily after at least 14 days. Schizophrenia in paediatric patients 13 to 17 years: 0.5 mg once daily Days 1-4, 1 mg/day Days 5-7, 2 mg on Day 8, then weekly increases in 1 mg increments; target 2-4 mg once daily, maximum 4 mg/day (this is a fixed mg schedule, not weight-based). Hepatic impairment (Child-Pugh score 7 or more): maximum 2 mg once daily for MDD or agitation with Alzheimer's dementia, 3 mg once daily for schizophrenia. Dose modifications for CYP2D6 poor metabolisers and CYP inhibitors/inducers — see interactions. No UK SPC (eMC) was present in this bundle, so the record is from US labelling and must be checked against the UK SPC before publication. The label's 'most common adverse reactions' list was cut off at the source-fetch limit (only 'Weight...' was visible for adjunctive MDD), so the side-effect list below is drawn from the adverse reactions the label highlights in section 6 rather than from an incidence-ranked list; sections 5, 6, 7, 8.1, 8.4 and 8.5 were all truncated.